A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study
Helena A Yu, Yasushi Goto, Pasi A Jänne · 2026
Read A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study by Helena A Yu, Yasushi Goto, Pasi A Jänne (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13685561.txt.
Description
Yu, Goto, and Jänne wrote a plain language summary, published in 2026, of a study of a drug for a common lung cancer. The cancer carried a change in one growth gene and had already grown after earlier treatment. The study, first reported in a medical journal in September 2023, enrolled 277 adults. It asked whether the new drug could shrink the cancer where older drugs had failed.
About 3 in every 10 patients responded to the drug at some point. The summary explains, in everyday words, how long the benefit lasted and which side effects showed up. It also explains why researchers are testing a drug that pairs a targeting antibody with a cell-killing payload. The piece is written for patients and families facing this cancer. It lets them weigh a new option without wading through a technical report.
Catalog record
| CREATOR | Helena A Yu, Yasushi Goto, Pasi A Jänne |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |